Surgery for recurrent ovarian cancer
Standard
Surgery for recurrent ovarian cancer. / Heitz, Florian; du Bois, Andreas; Kurzeder, Christian; Pfisterer, Jacobus; Barinoff, Jana; Grabowski, Jacek; Hilpert, Felix; Mahner, Sven; Harter, Philipp.
in: Womens Health (Lond Engl), Jahrgang 7, Nr. 5, 01.09.2011, S. 529-35.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Surgery for recurrent ovarian cancer
AU - Heitz, Florian
AU - du Bois, Andreas
AU - Kurzeder, Christian
AU - Pfisterer, Jacobus
AU - Barinoff, Jana
AU - Grabowski, Jacek
AU - Hilpert, Felix
AU - Mahner, Sven
AU - Harter, Philipp
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer. The role in recurrent ovarian cancer remains a field of discussion and controversy, mainly owing to missing data from prospective randomized trials and lack of universal definitions. Retrospective data indicate that complete resection of recurrent tumor formations should be aimed for, since survival prolongation is mainly seen for patients with no residual disease. Thus, it is most important to find predictors of complete resection, on the one hand to offer the best therapeutic chances to patients, but on the other hand to protect patients with limited life expectancy from additional surgical burden. The first prospective surgical trial in recurrent ovarian cancer, AGO-DESKTOP II validated a score ('AGO score') for complete resection. It was shown that patients with a good general condition (ECOG 0), no residual disease after surgery for primary ovarian cancer and absence of ascites in presurgical diagnostics have a 76% likelihood of undergoing complete resection. In this article, further recent data regarding surgery for recurrent ovarian cancer are going to be discussed and the advantages of incorporating these patients into randomized trials are highlighted.
AB - Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer. The role in recurrent ovarian cancer remains a field of discussion and controversy, mainly owing to missing data from prospective randomized trials and lack of universal definitions. Retrospective data indicate that complete resection of recurrent tumor formations should be aimed for, since survival prolongation is mainly seen for patients with no residual disease. Thus, it is most important to find predictors of complete resection, on the one hand to offer the best therapeutic chances to patients, but on the other hand to protect patients with limited life expectancy from additional surgical burden. The first prospective surgical trial in recurrent ovarian cancer, AGO-DESKTOP II validated a score ('AGO score') for complete resection. It was shown that patients with a good general condition (ECOG 0), no residual disease after surgery for primary ovarian cancer and absence of ascites in presurgical diagnostics have a 76% likelihood of undergoing complete resection. In this article, further recent data regarding surgery for recurrent ovarian cancer are going to be discussed and the advantages of incorporating these patients into randomized trials are highlighted.
KW - Antineoplastic Agents
KW - Antineoplastic Agents, Phytogenic
KW - Carboplatin
KW - Female
KW - Gynecologic Surgical Procedures
KW - Humans
KW - Medical Oncology
KW - Neoplasm Recurrence, Local
KW - Ovarian Neoplasms
KW - Paclitaxel
KW - Prognosis
KW - Survival Analysis
KW - Treatment Outcome
U2 - 10.2217/whe.11.52
DO - 10.2217/whe.11.52
M3 - SCORING: Journal article
C2 - 21879821
VL - 7
SP - 529
EP - 535
IS - 5
ER -
